SIM0505/CDH6 ADC dose optimization initiated in gynecologic cancers SIM0505 Phase 1 dose escalation study data to be presented at ASCO 2026 LNCB74 Phase 1 dose escalation trial update planned in second half of 2026 BELTSVILLE, Md., May 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc.
Dose optimization will initially be focused on evaluating SIM0505 in patients with platinum-resistant ovarian cancer (PROC) Phase 1 data readout to be presented at ASCO 2026 BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) Phase 1 data for SIM0505 to be presented at ASCO 2026; dose optimization in ovarian cancer expected to begin in Q2 2026 BELTSVILLE,
The American Society for Clinical Oncology to be held in Chicago May 29 – June 2, 2026 BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class
Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026 LNCB74 Phase 1 dose escalation trial update planned in second half of 2026 BELTSVILLE, Md., March 05, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc.
SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026 LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md. , Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to